Scientists probe hormone duo for appetite control clues

NCT ID NCT07506369

Recruiting now Knowledge-focused Sponsor: University Hospital, Gentofte, Copenhagen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how two natural hormones—amylin and pancreatic polypeptide—work together to control appetite and food intake. Eighteen healthy men will receive infusions of these hormones, alone or combined, and then eat a meal to see how much they consume. The goal is to better understand the body's hunger signals, which could one day lead to new obesity treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Amylin (Pramlintide) and Pancreatic Polypeptide
What this could lead to: If successful, this could help scientists understand how these hormones control appetite, potentially pointing toward new treatments for obesity.
What could go wrong: This is a small, early-stage study in healthy men only, so results may not apply to the general population or lead directly to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Center for Clinical Metabolic Research, Gentofte Hospital
RECRUITING

Hellerup, Capital Region, 2900, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.